A Phase 3 interventional study of Baricitinib and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 30 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-11.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 12th largest by enrollment, is the only one that started in 2014, is one of 8 in phase 3, and was the 11th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
Galvani Bioelectronics · Sites in United States, Netherlands
Ages 22–75
University of Nebraska · Sites in United States
Ages 19+
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 9
First in 2007; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 290 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 290 across the 23 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
35 studies in Arthritis, Rheumatoid by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 15th largest by enrollment, is the only one that started in 2014, is one of 11 in phase 3, and was the 26th registered.
Eli Lilly and Company’s Arthritis, Rheumatoid studies by the year they started, since 2005.
1 of the studies testing baricitinib in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05003310Galvani BioelectronicsConsideRAte Study - Splenic Stimulation for RA | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 35 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as baricitinib in participants with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks. Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline.
Drug: Baricitinib
Placebo administered orally once a day through week 24. At week 24, participants will be given 4 mg or 2 mg (participants with renal impairment) baricitinib orally once a day through Week 52. Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline.
Drug: Placebo
Administered orally
Also known as: LY3009104, INCB 028050
Administered orally
Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20)
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.
Time frame: Week 12
Change From Baseline to Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Disease Activity Score Modified to Include the 28 Diarthroidal Joint Count (DAS28)-High Sensitivity C-Reactive Protein (hsCRP)
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Baseline, Week 12
Proportion of Participants Achieving a Simplified Disease Activity Index (SDAI) Score < or Equal to 3.3
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Participant's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.
Time frame: Week 12
Median Duration of Morning Joint Stiffness in the 7 Days Prior to Week 12
Participants recorded the duration of their morning joint stiffness (MJS) in hours and minutes into paper diaries daily. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit was calculated. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
Time frame: Week 12
Mean Severity of Morning Joint Stiffness in the 7 Days Prior to Week 12
Participants rated the severity of their morning joint stiffness by selecting a number from 0 to 10 that best described their overall level of morning joint stiffness from the time they woke up, where 0 represents "no joint stiffness" and 10 represents "joint stiffness as bad as you can imagine". Participants reported their severity daily in paper diaries. The average value across the 7 days preceding each visit was calculated.
Time frame: Week 12
Mean Worst Tiredness Numeric Rating Scale (NRS) in the 7 Days Prior to Week 12
Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine". Participants reported their worst tiredness in paper diaries. The average value across the 7 days preceding each visit is calculated.
Time frame: Week 12
Mean Worst Pain NRS in the 7 Days Prior to Week 12
Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine". Participants reported their worst joint pain in daily paper diaries. The average value across the 7 days preceding each visit was calculated.
Time frame: Week 12
| Milestone | Placebo Treatment Period Week 0-24 | 4 Milligrams (mg) Baricitinib Treatment Period Week 0-24 | Rescue Treatment Period Week 16-52 | Placebo to Baricitinib Treatment Period Week 24 - 52 | 4 mg Baricitinib Treatment Period Week 24-52 | Placebo Follow-up Period | 4 mg Baricitinib Follow-up Period |
|---|---|---|---|---|---|---|---|
| Started | 145 | 145 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 145 | 145 | 0 | 0 | 0 | 0 | 0 |
| Rescued | 59 | 17 | 0 | 0 | 0 | 0 | 0 |
| Completed | 133 | 136 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 12 | 9 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Entry criteria not met | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Treatment Period Week 0-24 | 4 Milligrams (mg) Baricitinib Treatment Period Week 0-24 | Rescue Treatment Period Week 16-52 | Placebo to Baricitinib Treatment Period Week 24 - 52 | 4 mg Baricitinib Treatment Period Week 24-52 | Placebo Follow-up Period | 4 mg Baricitinib Follow-up Period |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 77 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 74 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Treatment Period Week 0-24 | 4 Milligrams (mg) Baricitinib Treatment Period Week 0-24 | Rescue Treatment Period Week 16-52 | Placebo to Baricitinib Treatment Period Week 24 - 52 | 4 mg Baricitinib Treatment Period Week 24-52 | Placebo Follow-up Period | 4 mg Baricitinib Follow-up Period |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 74 | 120 | 0 | 0 |
| Completed | 0 | 0 | 0 | 72 | 115 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 2 | 5 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Milestone | Placebo Treatment Period Week 0-24 | 4 Milligrams (mg) Baricitinib Treatment Period Week 0-24 | Rescue Treatment Period Week 16-52 | Placebo to Baricitinib Treatment Period Week 24 - 52 | 4 mg Baricitinib Treatment Period Week 24-52 | Placebo Follow-up Period | 4 mg Baricitinib Follow-up Period |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 2 | 58 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 | 47 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 11 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 1 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.
| percentage of participants | Placebo | Baricitinib |
|---|---|---|
| Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) | 28.3 | 58.6 |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
| units on a scale | Placebo | Baricitinib |
|---|---|---|
| Change From Baseline to Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) Score | -0.35 ± 0.52 | -0.57 ± 0.54 |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| units on a scale | Placebo | Baricitinib |
|---|---|---|
| Change From Baseline to Week 12 in Disease Activity Score Modified to Include the 28 Diarthroidal Joint Count (DAS28)-High Sensitivity C-Reactive Protein (hsCRP) | -0.94 ± 1.04 | -1.89 ± 1.14 |
SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Participant's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.
| Participants | Placebo | Baricitinib |
|---|---|---|
| Proportion of Participants Achieving a Simplified Disease Activity Index (SDAI) Score < or Equal to 3.3 | 0 | 2 |
Participants recorded the duration of their morning joint stiffness (MJS) in hours and minutes into paper diaries daily. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit was calculated. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.
| minutes | Placebo | Baricitinib |
|---|---|---|
| Median Duration of Morning Joint Stiffness in the 7 Days Prior to Week 12 | 47.6 (30.0 to 67.9) | 24.3 (15.0 to 30.6) |
Participants rated the severity of their morning joint stiffness by selecting a number from 0 to 10 that best described their overall level of morning joint stiffness from the time they woke up, where 0 represents "no joint stiffness" and 10 represents "joint stiffness as bad as you can imagine". Participants reported their severity daily in paper diaries. The average value across the 7 days preceding each visit was calculated.
| units on a scale | Placebo | Baricitinib |
|---|---|---|
| Mean Severity of Morning Joint Stiffness in the 7 Days Prior to Week 12 | 4.3 ± 2.3 | 3.5 ± 2.1 |
Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine". Participants reported their worst tiredness in paper diaries. The average value across the 7 days preceding each visit is calculated.
| units on a scale | Placebo | Baricitinib |
|---|---|---|
| Mean Worst Tiredness Numeric Rating Scale (NRS) in the 7 Days Prior to Week 12 | 4.4 ± 2.0 | 3.7 ± 1.9 |
Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine". Participants reported their worst joint pain in daily paper diaries. The average value across the 7 days preceding each visit was calculated.
| units on a scale | Placebo | Baricitinib |
|---|---|---|
| Mean Worst Pain NRS in the 7 Days Prior to Week 12 | 5.0 ± 1.8 | 4.1 ± 1.9 |
Collected over Start of treatment to end of study (Up To 52 Weeks). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Treatment Period Week 0-24 | 0/145 (0%) | 4/145 (2.8%) | 72/145 (49.7%) |
| 4 Milligrams (mg) Baricitinib Treatment Period Week 0-24 | 0/145 (0%) | 4/145 (2.8%) | 94/145 (64.8%) |
| Rescue Treatment Period Week 16-52 | 1/77 (1.3%) | 3/77 (3.9%) | 38/77 (49.4%) |
| Placebo to Baricitinib Treatment Period Week 24 - 52 | 0/74 (0%) | 7/74 (9.5%) | 31/74 (41.9%) |
| 4 mg Baricitinib Treatment Period Week 24-52 | 0/120 (0%) | 3/120 (2.5%) | 41/120 (34.2%) |
| Placebo Follow-up Period | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| 4 mg Baricitinib Follow-up Period | 0/58 (0%) | 1/58 (1.7%) | 3/58 (5.2%) |
| Event | Placebo Treatment Period Week 0-24 | 4 Milligrams (mg) Baricitinib Treatment Period Week 0-24 | Rescue Treatment Period Week 16-52 | Placebo to Baricitinib Treatment Period Week 24 - 52 | 4 mg Baricitinib Treatment Period Week 24-52 | Placebo Follow-up Period | 4 mg Baricitinib Follow-up Period |
|---|---|---|---|---|---|---|---|
| Subarachnoid haemorrhageInjury, poisoning and procedural complications | 0/145 | 0/145 | 0/77 | 0/74 | 0/120 | 0/2 | 1/58 |
| Intracranial aneurysmNervous system disorders | 0/145 | 0/145 | 0/77 | 0/74 | 0/120 | 0/2 | 1/58 |
| Angina unstableCardiac disorders | 0/145 | 0/145 | 0/77 | 1/74 | 0/120 | 0/2 | 0/58 |
| EnteritisGastrointestinal disorders | 0/145 | 0/145 | 0/77 | 1/74 | 0/120 | 0/2 | 0/58 |
| Lung infectionInfections and infestations | 0/145 | 0/145 | 0/77 | 1/74 | 0/120 | 0/2 | 0/58 |
| PneumoniaInfections and infestations | 0/145 | 0/145 | 1/77 | 1/74 | 0/120 | 0/2 | 0/58 |
| Viral infectionInfections and infestations | 0/145 | 0/145 | 0/77 | 1/74 | 0/120 | 0/2 | 0/58 |
| Spinal disorderMusculoskeletal and connective tissue disorders | 0/145 | 0/145 | 0/77 | 1/74 | 0/120 | 0/2 | 0/58 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/145 | 0/145 | 0/77 | 1/74 | 0/120 | 0/2 | 0/58 |
| Renal tubular acidosisRenal and urinary disorders | 0/145 | 0/145 | 0/77 | 1/74 | 0/120 | 0/2 | 0/58 |
| Event | Placebo Treatment Period Week 0-24 | 4 Milligrams (mg) Baricitinib Treatment Period Week 0-24 | Rescue Treatment Period Week 16-52 | Placebo to Baricitinib Treatment Period Week 24 - 52 | 4 mg Baricitinib Treatment Period Week 24-52 | Placebo Follow-up Period | 4 mg Baricitinib Follow-up Period |
|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 22/145 | 28/145 | 7/77 | 5/74 | 11/120 | 0/2 | 0/58 |
| Urinary tract infectionInfections and infestations | 5/145 | 13/145 | 10/77 | 4/74 | 3/120 | 0/2 | 0/58 |
| HyperlipidaemiaMetabolism and nutrition disorders | 8/145 | 16/145 | 6/77 | 3/74 | 9/120 | 0/2 | 0/58 |
| AnaemiaBlood and lymphatic system disorders | 14/145 | 12/145 | 0/77 | 0/74 | 0/120 | 0/2 | 0/58 |
| NasopharyngitisInfections and infestations | 6/145 | 10/145 | 6/77 | 4/74 | 4/120 | 0/2 | 0/58 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/145 | 0/145 | 0/77 | 0/22 | 1/14 | 0/2 | 0/58 |
| Blood creatine phosphokinase increasedInvestigations | 0/145 | 9/145 | 5/77 | 5/74 | 2/120 | 0/2 | 0/58 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/145 | 0/145 | 2/77 | 1/74 | 3/120 | 0/2 | 3/58 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/145 | 9/145 | 3/77 | 2/74 | 1/120 | 0/2 | 0/58 |
| HeadacheNervous system disorders | 8/145 | 5/145 | 0/77 | 0/74 | 0/120 | 0/2 | 0/58 |
Modified Intent-to-Treat (mITT) population includes all randomized participants who received at least one dose of the study drug.
| Age, Continuous(years) | Placebo | Baricitinib | Total |
|---|---|---|---|
| Mean | 48.9 ± 12.7 | 49.5 ± 10.6 | 49.2 ± 11.7 |
| Sex: Female, Male(Participants) | Placebo | Baricitinib | Total |
|---|---|---|---|
| Female | 106 | 127 | 233 |
| Male | 39 | 18 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Baricitinib | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 115 | 116 | 231 |
| Unknown or Not Reported | 30 | 29 | 59 |
| Race (NIH/OMB)(Participants) | Placebo | Baricitinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 5 | 6 |
| Asian | 115 | 116 | 231 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 26 | 24 | 50 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Baricitinib | Total |
|---|---|---|---|
| Argentina | 22 | 21 | 43 |
| China | 115 | 116 | 231 |
| Brazil | 8 | 8 | 16 |
| Duration of Rheumatoid Arthritis(years) | Placebo | Baricitinib | Total |
|---|---|---|---|
| Mean | 9.1 ± 7.0 | 10.7 ± 8.3 | 9.9 ± 7.7 |
| Tender Joint Count of 68 Evaluable Joints(Tender Joints) | Placebo | Baricitinib | Total |
|---|---|---|---|
| Mean | 25.2 ± 14.7 | 23.3 ± 13.6 | 24.2 ± 14.2 |
| Swollen Joint Count of 66 Evaluable Joints(Swollen Joints) | Placebo | Baricitinib | Total |
|---|---|---|---|
| Mean | 14.8 ± 9.5 | 14.6 ± 8.6 | 14.7 ± 9.1 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Oct 2014, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib